Bio-Gene Technology Ltd (BGT) — Cash Flow Reinvestment Rate

Latest as of June 2022: 0.31x

Bio-Gene Technology Ltd (BGT) has a Cash Flow Reinvestment Rate of 0.31x as of June 2022, reinvesting AU$13.68K (capex AU$6.84K plus investments AU$-6.84K) from operating cash flow of AU$43.52K. Explore BGT capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.31x

(Capex + Investments) / Operating CF

Total Reinvested

AU$13.68K

Capex + Investments

Operating Cash Flow

AU$43.52K

AUD

Capital Expenditures

AU$6.84K

AUD

Bio-Gene Technology Ltd Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Bio-Gene Technology Ltd across 1 annual periods. Also explore BGT total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Bio-Gene Technology Ltd (2022–2022)

Year-by-year capital reinvestment analysis for Bio-Gene Technology Ltd. For live market cap and broader valuation context, see Bio-Gene Technology Ltd market capitalisation.

Year	Reinvestment Rate	Total Reinvested (AUD)	Operating CF	Capex	YoY Change
2022	0.31x	AU$13.68K	AU$43.52K	AU$6.84K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow